Pipeline:

Drug: OR-102 for the treatment of sensineural hearing loss

Drug: OR-105 for the treatment of Meniere’s Disease

Drug: OR-107 for the treatment of ototoxicity

Drug: OR-110 for the use with cochlear implants

 

Technology:

The innovation in our products lies in the unique synthesis of particle production, coating methodologies, drug targets and novel indications. There are no approved drugs for common and severe diseases of the inner ear such as presbycusis, and there are no intracochlear drug delivery systems available for the treatment of any inner ear disease. The development of such formulations could have a dramatic effect.